FDA Is Rewriting the Premarket Rulebook. Cigar Makers Should Pay Attention.

On September 28, 2026, FDA said it intends to write a new rule to replace the 2021 framework that governs premarket tobacco product applications. Ten days later, a federal court in Lubbock paused the Altria-backed lawsuit that helped prompt the announcement.

Almost every story about this has been written for the vape and nicotine pouch trade. That is understandable, since those products drive the application backlog. But the 2021 rule was never limited to e-cigarettes. It governs every new tobacco product that needs a marketing order through the PMTA pathway, combustibles included. It is also where the federal definition of a premium cigar is written down. For cigar manufacturers and importers, a rewrite of this rulebook is not a vape story. It is theirs too.

What FDA announced, and what it left out

FDA's statement is three short paragraphs. The agency said it is reviewing its experience implementing the 2021 PMTA rule and recent court developments, including a lawsuit in the Northern District of Texas. It cited the growth of an illicit and unregulated market and the pace of new product introductions. On that basis, it intends to evaluate changes to the framework, including new rulemaking to replace it.

Three commitments came with it. FDA will keep processing applications and issuing decisions under current requirements in the meantime. It will keep applying the statutory standard of whether a product is appropriate for the protection of the public health. And any change will come with an opportunity for public comment.

What the statement does not contain matters as much. There is no proposed rule, no timetable and no description of what a replacement would look like. It names no product category and does not mention cigars. It also says nothing about the companion rule FDA issued the same day in 2021 governing substantial equivalence reports, which is the pathway most cigar products actually use.

The rule under review is titled Premarket Tobacco Product Applications and Recordkeeping Requirements, published October 5, 2021 at 86 FR 55300 and effective November 4, 2021. Most of it sits in 21 C.F.R. Part 1114, which sets what an application must contain and how FDA reviews it. But the same rule also amended Parts 1100 and 1107 to require manufacturers to keep records proving their products are legally marketed. That second piece is the one cigar companies should be reading closely.

The lawsuit behind the announcement

The case FDA referred to was filed September 2, 2026 in the Lubbock Division of the Northern District of Texas, No. 5:26-cv-00199-H. The plaintiffs are two Altria subsidiaries, Helix Innovations (on! nicotine pouches) and NJOY (e-cigarettes), joined by the Texas Food & Fuel Association and two Texas retailers. They ask the court to vacate the 2021 rule.

The core theory is about the clock. The Tobacco Control Act requires FDA to act on a PMTA as promptly as possible and no later than 180 days after receiving it. The plaintiffs argue the 2021 rule moved the start of that clock by inserting acceptance and filing phases before substantive review begins, and that the rule is arbitrary and capricious on other grounds as well. Three Reynolds companies have moved to intervene on the plaintiffs' side.

The day after FDA's announcement, the parties jointly asked the court to pause the case. Judge James Wesley Hendrix granted the stay on October 8. The order is procedural; no court has ruled on the merits. The case is now parked while FDA writes, and the joint status reports the court ordered are a useful marker of how fast the agency is actually moving.

The Texas case is not the only pressure. On August 19, 2026, the Fifth Circuit held in NicQuid v. FDA that a review standard FDA had applied through individual decisions was in substance a rule requiring notice and comment. That ruling points the same direction: if FDA wants to change how it judges applications, it needs to do so through rulemaking.

Which cigars this reaches

The premium exemption is narrower than many in the trade assume. On April 15, 2026, the district court in Cigar Association of America v. FDA reaffirmed the definition that decides which cigars sit outside FDA's deeming rule, as discussed in The Line Holds. A cigar qualifies only if it meets all eight elements:

1. Wrapped in whole tobacco leaf
2. A 100 percent leaf tobacco binder
3. At least 50 percent long filler tobacco, by weight of the filler
4. Handmade or hand rolled
5. No filter, nontobacco tip or nontobacco mouthpiece
6. No characterizing flavor other than tobacco
7. Only tobacco, water and vegetable gum, with no other ingredients or additives
8. More than 6 pounds per 1,000 units

Miss one element and the cigar is back inside the full premarket system. That includes every flavored or infused cigar, every cigarillo and little cigar, machine-made cigars, tipped or filtered cigars, and handmade cigars that fall short on filler, binder, additives or weight.

For those products, the statute still controls. A product first marketed in the United States after February 15, 2007, or modified after that date, is a new tobacco product. It needs an order through one of three doors: a substantial equivalence report, an exemption from substantial equivalence or a PMTA. Products on the market on that date are pre-existing, or grandfathered, and need no order at all, provided the manufacturer can prove the date.

Why a PMTA rewrite matters to cigar makers

Most new cigar products reach the market through substantial equivalence, not a PMTA. On its face, then, a PMTA rewrite looks like someone else's problem. There are four reasons it is not.

First, the premium definition lives in Part 1114. Section 1114.1(d) states that Part 1114 does not apply to premium cigars as defined in § 1114.3, and § 1114.3 is where the federal definition is codified. States now borrow that citation; California's Unflavored Tobacco List keys its fast track for premium cigars to § 1114.3, as discussed in Check the Box. A replacement rule will have to carry the definition and the carve-out forward. The court order would still control as a matter of federal law, but the regulatory text that states and counterparties cite should not be allowed to drift from it, and the premium side of the industry should be watching for exactly that.

Second, the grandfather records live in this rule. The 2021 rule created Subpart C of 21 C.F.R. Part 1100, which requires any manufacturer that ships a pre-existing product to keep dated evidence that it was on the U.S. market as of February 15, 2007, and to retain that evidence for at least four years. The same rule added recordkeeping for products marketed under an exemption from substantial equivalence. Those records are the foundation of every grandfathered cigar line and of every predicate an SE report relies on. FDA's announcement speaks of replacing the current framework without saying whether these provisions are in scope. A replacement could carry them over unchanged, tighten them or relax them. Until FDA publishes a proposal, no one can say which.

Third, the timing dispute travels. The Helix complaint attacks how FDA starts the clock: acceptance review, then filing review, then substantive review. SE reports pass through FDA's own acceptance and review procedures as well. If FDA rebuilds the PMTA process around faster, more predictable intake, pressure to do the same for SE will follow, and cigar applicants with long-pending reports have an interest in saying so on the record.

Fourth, some cigars have no predicate. A genuinely new cigar format, or a flavored product with no grandfathered comparator, cannot use substantial equivalence. For that product, the PMTA is the only door, and the 2021 rule governs it today. What evidence FDA demands, and how it sorts combustible products from vapes and pouches, will decide whether that door is usable for a mid-sized cigar company at all.

The SE pathway has its own 2021 rule, published the same day at 86 FR 55224 and codified in Part 1107. FDA's announcement does not mention it. Cigar makers should not read that silence as a promise that the SE rules will stay put, or as a signal that they will change.

What to watch, and what to do now

Nothing changes today. FDA has said the current rules apply until a new one is final, and rulemaking of this kind runs from a proposed rule through a comment period to a final rule. That is months at the earliest. The useful work is preparation.

• Pull the grandfather file. For every product sold as pre-existing, or used as a predicate, confirm that the dated evidence of February 15, 2007 marketing is in hand, legible and retained. If a new framework tightens these requirements, the companies with complete files will feel it least.
• Re-run the eight-element test. Check each cigar in the line against the premium definition, element by element. A blend change, a new wrapper, an added tip or a lighter vitola can move a product from exempt to regulated without anyone noticing.
• Watch the Federal Register. The proposed rule is where the scope question gets answered: whether the premium definition, the Part 1100 and Part 1107 recordkeeping provisions or the review procedures are reopened, and whether combustibles get their own track.
• Plan to comment. The 2021 rule put every product category in one framework. If cigar companies want rules that fit cigars, the comment period is the place to ask for them.
• Track the Texas docket. The joint status reports the court ordered when it entered the stay are the most reliable public measure of how fast FDA is actually moving.